Tremelimumab AstraZeneca Unione Europea - italiano - EMA (European Medicines Agency)

tremelimumab astrazeneca

astrazeneca ab - tremelimumab - carcinoma, polmone non a piccole cellule - agenti antineoplastici - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Imjudo Unione Europea - italiano - EMA (European Medicines Agency)

imjudo

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - agenti antineoplastici - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Imjudo 25 mg/1,25 ml Concentrato per soluzione per Infusione Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

imjudo 25 mg/1,25 ml concentrato per soluzione per infusione

astrazeneca ag - tremelimumabum - concentrato per soluzione per infusione - tremelimumabum 25 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, dinatrii edetas corresp. natrium 0.012 mg, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1.25 ml. - hepatozelluläres karzinom - biotechnologika

Imjudo 300 mg/15 ml Concentrato per soluzione per Infusione Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

imjudo 300 mg/15 ml concentrato per soluzione per infusione

astrazeneca ag - tremelimumabum - concentrato per soluzione per infusione - tremelimumabum 300 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, dinatrii edetas corresp. natrium 0.185 mg, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 15 ml. - hepatozelluläres karzinom - biotechnologika

Imfinzi Unione Europea - italiano - EMA (European Medicines Agency)

imfinzi

astrazeneca ab - durvalumab - carcinoma, polmone non a piccole cellule - agenti antineoplastici - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Cinqaero Unione Europea - italiano - EMA (European Medicines Agency)

cinqaero

teva b.v. - reslizumab - asma - altri farmaci sistemici per le malattie respiratorie ostruttive, - cinqaero è indicato come terapia aggiuntiva nei pazienti adulti con asma eosinofilico grave non adeguatamente controllato nonostante i corticosteroidi inalati con dosi elevate più un altro medicinale per il trattamento di mantenimento.

Tevimbra Unione Europea - italiano - EMA (European Medicines Agency)

tevimbra

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - agenti antineoplastici - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Tevimbra 100 mg / 10 ml  Konzentrat zur Herstellung einer Infusionslösung Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

tevimbra 100 mg / 10 ml konzentrat zur herstellung einer infusionslösung

beigene switzerland gmbh - tislelizumabum - 100 mg / 10 ml konzentrat zur herstellung einer infusionslösung - tislelizumabum 100 mg, natrii citras dihydricus, acidum citricum monohydricum, histidini hydrochloridum monohydricum, histidinum, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 16 mg. - onkologikum - biotechnologika

Cinqaero 100 mg/10 mL Concentrato per soluzione per Infusione Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

cinqaero 100 mg/10 ml concentrato per soluzione per infusione

teva pharma ag - reslizumabum - concentrato per soluzione per infusione - reslizumabum 100 mg, saccharum, natrii acetas trihydricus, acidum aceticum glaciale, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 1.41 mg. - aggiuntiva in caso di grave eosinophilem asma negli adulti - biotechnologika

Cinqaero 25 mg/2,5 mL Concentrato per soluzione per Infusione Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

cinqaero 25 mg/2,5 ml concentrato per soluzione per infusione

teva pharma ag - reslizumabum - concentrato per soluzione per infusione - reslizumabum 25 mg, saccharum, natrii acetas trihydricus, acidum aceticum glaciale, aqua ad iniectabile q.s. ad solutionem pro 2.5 ml corresp. natrium 0.35 mg. - aggiuntiva in caso di grave eosinophilem asma negli adulti - biotechnologika